36,054 Shares in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Purchased by Stonebridge Financial Group LLC

Stonebridge Financial Group LLC acquired a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 36,054 shares of the company’s stock, valued at approximately $286,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in AMRX. Entropy Technologies LP purchased a new position in Amneal Pharmaceuticals during the 4th quarter valued at about $259,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at approximately $81,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Amneal Pharmaceuticals during the fourth quarter valued at approximately $520,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management boosted its position in shares of Amneal Pharmaceuticals by 13.6% in the 4th quarter. Empirical Financial Services LLC d.b.a. Empirical Wealth Management now owns 46,240 shares of the company’s stock worth $366,000 after purchasing an additional 5,523 shares in the last quarter. Finally, Janney Montgomery Scott LLC purchased a new stake in shares of Amneal Pharmaceuticals in the 4th quarter worth approximately $121,000. Hedge funds and other institutional investors own 31.82% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Piper Sandler lifted their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday, November 11th. StockNews.com cut shares of Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, December 19th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.00.

Insider Transactions at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, Director Gautam Patel sold 80,000 shares of the firm’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $8.14, for a total value of $651,200.00. Following the transaction, the director now directly owns 1,888,886 shares of the company’s stock, valued at approximately $15,375,532.04. This trade represents a 4.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Jason B. Daly sold 43,657 shares of the company’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $8.61, for a total transaction of $375,886.77. Following the sale, the senior vice president now directly owns 13,665 shares of the company’s stock, valued at $117,655.65. The trade was a 76.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 203,657 shares of company stock worth $1,667,887 in the last ninety days. Insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Trading Up 0.1 %

Shares of AMRX stock opened at $7.96 on Wednesday. Amneal Pharmaceuticals, Inc. has a 12-month low of $5.01 and a 12-month high of $9.48. The stock has a market capitalization of $2.47 billion, a P/E ratio of -11.71 and a beta of 1.10. The firm’s 50 day moving average is $8.12 and its 200 day moving average is $8.25.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.